112 search results for: symposium
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this soundbite video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson highlights the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson explores how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the importance of early, effective treatment to alter disease progression.
ADVENT in Orlando, 2025
Type 2 inflammation contributes to many dermatologic diseases, which may lead to potentially life-changing burdens and challenges to patients and caregivers. By uncovering the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP, we can move forward in our understanding of each disease. Join global experts for an educational symposium on March 8th that will uncover the role of type 2 inflammation in the pathophysiology of AD, PN, CSU, and BP and explore questions driving current research in each disease.
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression
ERS 2024 | Pediatric Severe Asthma: Is Clinical Remission Possible?
Watch as Leonard Bacharier, MD, and Sharon Dell, MD, FRCPC, discuss the concept of clinical remission in pediatric severe asthma.
On the Surface: Restoring the Skin Barrier in Patients with AD
In this clip from the April WCPD 2025 symposium, Dr Amy Paller highlights CCL17 (TARC) as an important biomarker in AD.
How do You Define Active Disease (CRSwNP) When Looking at the Nose With an Endoscope?
In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Can Chronic Rhinosinusitis With Nasal Polyps be Considered in Remission if the Patient has an Impaired Sense of Smell?
Dr. Backer discusses assessing remission in CRSwNP by evaluating the patient's sense of smell in this video clip from the EAACI 2024 symposium.
Digging Deeper: Reducing Non-Atopic Comorbidities and Multidimensional Disease Burden
In this clip from the April WCPD 2025 symposium, Dr Paula Luna discusses how moderate-to-severe AD may hinder growth in pediatric patients.
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga discusses data identifying atopic dermatitis as the first diagnosed atopic disease and the start of the atopic march.
Charting the Future: Preventing the Atopic March
In this clip from the April WCPD 2025 symposium, Dr Eulàlia Baselga highlights the multidimensional burden of uncontrolled AD and how the various burdens contribute to Cumulative Life Course Impairment (CLCI).
ERS-ISIAN 2025 | Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions
The ERS-ISIAN 2025 symposium, featuring Prof. Vibeke Backer and Prof. Sietze Reitsma, titled "Type 2 Inflammation and Disease Control in CRSwNP: Current Perspectives and Future Directions," will delve into the complexities of the role of type 2 inflammation in CRSwNP.
Head-to-Head Trials of Biologics in CRSwNP
In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Sietze Reitsma discusses findings from the EVEREST trial, the first head-to-head study comparison of dupilumab and omalizumab in patients with severe CRSwNP and coexisting asthma. It also introduces the ongoing TORNADO study.
